Humana has a P/E ratio of 16.4 based on its 12 month trailing earnings per share of $14.17. Considering its future earnings ...

UnitedHealth Group Incorporated's stock faces a steep decline amid leadership turmoil, regulatory pressures, and rising costs ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases. Surging medical costs and regulatory changes hit ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Humana Inc. closed 37.79% short of its 52-week high of $406.46, which the company reached on July 18th.

Shares of Humana Inc. HUM shed 1.51% to $249.53 Friday, on what proved to be an all-around grim trading session for the stock ...

The standing of Humana among financial experts is revealed through an in-depth exploration of recent analyst actions. The ...

CVS Health sees strong Q1 2025 growth, but risks loom with downgraded revenue guidance and Medicare challenges. Read my ...

Q1 2025 Earnings Call Transcript April 30, 2025 Humana Inc. beats earnings expectations. Reported EPS is $11.58, expectations ...

In premarket trading, Humana’s stock rose 6.03%, reflecting investor confidence in the company’s robust performance and strategic outlook. According to InvestingPro analysis, Humana currently appears ...

Humana Inc. (NYSE:HUM) on Wednesday posted a first-quarter adjusted EPS of $11.58, up from $7.23 a year ago, beating the ...